Yves Ribeill, Ph.D.

Yves Ribeill, Ph.D.

Executive Chair of the Board

Dr. Yves Ribeill has served as a member of our Board since July 2018 and was appointed as the Executive Chair of the Board of Directors since February 2021. In his capacity as Executive Chair, Dr. Ribeill serves as the Company’s principal executive officer until a new Chief Executive Officer is appointed. Dr. Ribeill served as Calyxt’s interim Chief Executive Officer from August 2018 until October 2018. Since August 2017, he has served as the Chief Executive Officer of Ribogenics, Inc., which is a private biotechnology company working on microbiome re-engineering. Dr. Ribeill was also a founder of Scynexis, Inc. (NASDAQ: SCYX), served as its President from November 1999 until July 2015 and served as its Chief Executive Officer from November 1999 until April 2015. Before his work with Scynexis, Dr. Ribeill served in various positions during the 35 years of his international career with Rhone-Poulenc, Aventis including Discovery Chemistry Group leader for Anti-Viral Research and later in the Central Nervous System Group in France. He also served as Group Leader in the Cardiovascular Group in England. Upon his return to France, Dr. Ribeill served as Director of Chemistry for the Anti-Infective Group. He was involved in all phases of the drug discovery and development effort that resulted in the FDA approval of multiple drugs. He served as a Director of Scynexis, Inc. from November 1999 to March 2016 and has been a director of various other biotechnology companies in Europe and the United States. He is the author of more than 26 publications and 15 patents. He was a member of the Scientific Advisory Committee of the World Health Organization and of the Medicine Malaria Venture in Geneva. Dr. Ribeill has a Ph.D. in Chemistry from the University of Montpellier.

Bill Koschak

Bill Koschak

Chief Financial Officer

Bill brings over brings over 10 years of corporate, finance and accounting leadership to Calyxt as an operating or corporate CFO. Prior to joining Calyxt, Bill was Vice President, Finance for the Brain Therapies business unit of Medtronic (NYSE: MDT). He has held executive positions at Young America Holdings, General Mills (NYSE:GIS), and KPMG LLP. Bill was recognized as a CFO of the Year by the Twin Cities Business Journal in 2016 and currently serves on the board of 1st Financial Bank USA and Second Harvest Heartland.

Sarah Reiter

Sarah Reiter

Chief Business Officer

Sarah brings to Calyxt over 25 years of broad commercial leadership and expertise in agribusiness with focus on building markets for emerging technologies. She received her Master’s Certificate in Business Analysis from the Villanova School of Continuing Education and her Bachelor’s degree from the University of California, Davis. Prior to joining Calyxt in October 2020, Sarah held commercial leadership roles at Arcadia Bioscience, Bayer Crop Science, Syngenta and served as a CEO of Stockton U.S.A.

Travis Frey

Travis Frey

Chief Technology Officer

Travis brings over 15 years of experience in the agricultural industry and technology innovation to Calyxt. Travis received his B.S. in Horticulture from Penn State University, M.S. in Plant Breeding and Plant Genetics from the University of Wisconsin, Ph.D. in the Plant Biology and Biotechnology Program at the University of Delaware and DuPont/Pioneer and an M.B.A from the University of Chicago – Booth School of Business. Prior to joining Calyxt, Travis held science and innovation leadership roles at WISErg Corporation and Monsanto.

Debra Frimerman

Debra Frimerman

General Counsel and Corporate Secretary

Debra brings agriculture and food industry legal expertise to Calyxt. Previously, Debra was Associate General Counsel for Syngenta North America and acting general counsel for Syngenta Seeds, LLC. Through her seven years at Syngenta, Debra provided counsel for executive leadership teams and contributed to the closing of numerous global transactions; launching new products into new markets; and developing regulatory, compliance and corporate policies. Prior to her role at Syngenta, Debra practiced law at Stoel Rives LLP and Lindquist & Vennum PLLP.